The in vitro activities of ABT-773, erythromycin, clarithromycin, and azithromycin were compared. ABT-773 was the most active compound against macrolide-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Enterococcus spp. and multidrugresistant Streptococcus pneumoniae. It also had good activity against gram-negative and atypical respiratory tract pathogens and Helicobacter pylori.
Macrolide antibiotics are used for treating community-acquired respiratory tract infections (1) . Ketolides, erythromycin analogs in which a ketone functionality replaces the threeposition cladinose, demonstrate in vitro antibacterial activity and in vivo efficacy in animal models of infection (3, 11) . In addition, many ketolides retain potency against macrolide-resistant strains of streptococci (2, 3, 11) due to dimethylation of the 23S rRNA by Erm methylases or by macrolide-specific efflux pumps (3, 14, 15) .
In addition to the ketone group at position 3, the novel ketolide ABT-773 is modified by an O-allyl-3-quinoline at the 6 position and a cyclized carbamate group between the 11 and 12 positions (11) . This study evaluated the potency and spectrum of ABT-773. The MIC ranges and MICs inhibiting 50 (MIC 50 ) and 90% (MIC 90 ) of the tested strains are presented in Tables 1 and 2. ABT-773, azithromycin, and clarithromycin were prepared at Abbott Laboratories, Abbott Park, Ill. Erythromycin, clindamycin, and penicillin reference powders were purchased from U.S. Pharmacopeial Convention, Inc., Rockville, Md.
Clinical isolates or reference strains obtained from the American Type Culture Collection (Manassas, Va.) were tested. The molecular mechanisms of macrolide resistance were identified by PCR amplification of the mef and erm genes (14, 15) and in Helicobacter pylori and Mycobacterium avium by DNA sequence analysis for mutations in 23S rRNA (8, 16) .
MICs were determined by agar dilution or broth microdilution as described by the National Committee for Clinical Laboratory Standards (NCCLS) (9) . Mueller-Hinton agar was supplemented with 5% sheep blood for testing Streptococcus pyogenes, Listeria monocytogenes, and Moraxella catarrhalis; the plates were incubated in an atmosphere containing 5% CO 2 for tests of S. pyogenes and M. catarrhalis. Quality control results met NCCLS standards (9, 10) . The susceptibilities of Legionella spp., M. avium, Mycoplasma pneumoniae, Borrelia burgdorferi, and Chlamydia trachomatis were determined as described previously (5, 6, 7, 13, 18 pneumoniae, demonstrating MICs of Ͻ0.015 g/ml. The MIC for ABT-773 against a single strain of C. trachomatis was 0.015 g/ml, similar to the activity against Chlamydia pneumoniae (17) .
The MIC 90 s for ABT-773 were 0.25 and 0.03 g/ml for inducible ErmA and susceptible strains of S. aureus and S. pyogenes. In contrast, macrolide MICs were more than 100-fold higher against inducible ErmA strains than against susceptible strains. Moreover, ABT-773 did not induce resistance to clindamycin in these strains by the disk approximation test; erythromycin induced resistance to both ABT-773 and clindamycin (data not shown; 12). These results suggest that ABT-773 does not induce 23S rRNA methylation in inducible ErmA strains.
Although the macrolides and clindamycin were inactive against constitutive ErmB strains of S. pneumoniae and S. pyogenes, the ABT-773 MIC 90 for ErmB strains of S. pneumoniae was 0.25 g/ml, and all ErmB strains of S. pyogenes were inhibited by Յ8 g/ml. The difference in activity of ABT-773 was likely due to the use of agar dilution with incubation in CO 2 to test S. pyogenes and broth microdilution to test S. pneumoniae and not to inherent species-dependent differences in susceptibility to ABT-773, since other studies show that the MIC 90 s for ErmB strains of S. pneumoniae and S. pyogenes are similar when the susceptibilities of both species are determined by broth microdilution (V. D. Shortridge, unpublished data). The potent activity of ABT-773 against constitutive ErmB streptococci may be due to its affinity for methylated ribosomes, and ABT-773 may not effectively induce higher levels of ribosome methylation in ErmB strains (4) . This may also ex- Contined on following page Penicillin susceptibility had no effect on susceptibility to ABT-773 for pneumococci. For macrolide-susceptible strains, the ABT-773 MIC 90 was 0.002 g/ml for 16 penicillin-susceptible strains and Յ0.002 g/ml for 14 penicillin-nonsusceptible strains. The ABT-773 MIC 90 s were 0.06, 0.06, and 0.12 g/ml for 27 penicillin-susceptible, 19 penicillin-intermediate, and 37 penicillin-resistant strains, respectively. Each group comprised macrolide-susceptible, MefA, and ErmB isolates. The MIC 90 s of ABT-773 in a study of 1,601 pneumococci are similar: Յ0.008, 0.03, and 0.12 g/ml for penicillin-susceptible, -intermediate, and -resistant strains, respectively (2).
ABT-773 was fourfold less active than clarithromycin against macrolide-susceptible strains of H. pylori and M. avium, with MIC 90 s of 0.06 and 64 g/ml, respectively. Point mutations in the 23S rRNA at residues A2058 and A2059 (E. coli numbering) reduce macrolide binding to ribosomes and result in resistance in H. pylori and M. avium (8, 16) . ABT-773 was significantly less active against H. pylori strains having A2058G or A2059G mutations and against M. avium strains having mutations at A2058 than against the corresponding susceptible strains. These results confirmed the importance of A2058 and A2059 for ABT-773 binding to ribosomes (4) .
Minimum bacterial concentrations (MBCs) were determined in conjunction with broth microdilution MICs for four strains (5, 9) . ABT-773 is 87 to 96% bound to human plasma proteins. The MICs and MBCs were also done in medium containing 50% (vol/vol) human serum (Scantibodies Laboratory, Inc., Santee, Calif.) which had been heated for 1 h at 56°C (Table 3) . ABT-773 was bactericidal for single strains of H. influenzae, S. pneumoniae, and M. catarrhalis in medium alone or in medium containing 50% human serum, since the MBCs were no more than twofold higher than the corresponding MICs. In contrast, ABT-773 was bacteriostatic for a strain of S. aureus.
MBC results were confirmed by time-kill analysis using ABT-773 at four times the MIC (Fig. 1) (5) . For H. influenzae, S. pneumoniae, and M. catarrhalis in medium alone or in medium containing 50% human serum, the number of viable cells remaining after 24 h of incubation with ABT-773 was reduced by at least 99.9% from the number of viable cells present in the initial inocula. For S. aureus, ABT-773 caused less than a 10-fold loss of viable cells after 24 h of incubation. Table 4 . s, drug-free control in medium; ᮀ, ABT-773 at four times the MIC in medium; F, drug-free control in medium containing 50% human serum, E, ABT-773 at four times the MIC in medium containing 50% human serum.
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